Related Experiment Video
Updated: Sep 27, 2025
03:37
Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
Published on: December 20, 2024
670
Duodenal Follicular Lymphoma: Track or Treat?
M Varanese1, A Lauro1, I Lattina2
1Department of Surgical Sciences, Sapienza University, Rome, Italy.
Digestive Diseases and Sciences
|April 8, 2022
Summary
Duodenal follicular lymphoma (DFL), a rare gastrointestinal cancer, can present in advanced stages. Combination chemoimmunotherapy, specifically Rituximab-Bendamustine, effectively achieved complete remission in a stage IV DFL patient.
Area of Science:
- Gastroenterology
- Hematology
- Oncology
Background:
- Duodenal follicular lymphoma (DFL) is a rare gastrointestinal non-Hodgkin's lymphoma, recognized as a distinct entity in 2016.
- DFL typically presents in early stages, predominantly in the second duodenal portion, and usually has a favorable prognosis.
Observation:
- A 74-year-old male presented with epigastric pain, and gastroscopy revealed white mucosal nodules.
- Pathological diagnosis confirmed grade 1-2 DFL. Staging revealed stage IV disease with spleen, tongue base lesions, and latero-cervical adenopathy.
Findings:
- The case highlights an advanced stage IV presentation of DFL, which is uncommon.
- Literature review emphasized the importance of combination therapy for advanced-stage DFL.
- The patient achieved complete remission following chemoimmunotherapy with the Rituximab-Bendamustine regimen.
Implications:
- This case underscores the potential for DFL to present with advanced-stage disease.
- Chemoimmunotherapy, particularly Rituximab-Bendamustine, demonstrates efficacy in achieving remission for advanced DFL.
- Further research into optimal treatment strategies for advanced DFL is warranted.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
443
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
443
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:29Chronic Pancreatitis II: Collaborative Care
133
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
133